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Background: Adrenocortical carcinoma is a rare malignancy and rare cause of Cushing’s syndrome.
Case presentation: A 65-year-old seemingly well male patient was referred to our clinic under the suspicion of
hyperaldosteronism due to hypertension combined with hypokalemia. However, his serum aldosterone and plasma
renin activity were within normal limits. Instead, Cushing’s syndrome was diagnosed by elevated urine free cortisol
and a non-suppressible dexamethasone test. Abdominal computed tomography showed a 7.8 × 4.8 cm mass lesion
at the right adrenal gland with liver invasion. Etomidate infusion was performed to reduce his cortisol level before
the patient received a right adrenalectomy and liver wedge resection. The pathology report showed adrenocortical
carcinoma with liver and lymph node metastasis. According to the European Network for the Study of Adrenal
Tumors (ENSAT) staging system, the tumor was classified as T4N1M1, stage IV. Recurrent hypercortisolism was
found shortly after surgery. The patient died of Fournier’s gangrene with septic shock on the 59th day after
diagnosis.
Conclusions: We report a case of rapidly progressive stage IV adrenocortical carcinoma with initial presentations of
hypokaelmia and hypertension, mimicking hyperaldosteronism.
Keywords: Adrenocortical carcinoma, Cushing’s syndrome, HyperaldosteronismBackground
Adrenocortical carcinoma (ACC) is a rare malignancy,
with an incidence of 0.7-2.0/million population/year [1].
Approximately 50 to 60% of cases of ACC present with an
excess of adrenal steroid hormone, with the most com-
mon form being Cushing’s syndrome with hypercor-
tisolism. Less frequently, an excess of sex hormones,
including androgen or estrogen, may cause virilization in
women and feminization in men [1]. Hypertension and
profound hypokalemia may be due to mineralocorticoid
excess. However, true hyperaldosteronism is rare [2].
The clinical presentations of ACC are heterogeneous
and the prognosis is generally poor. Although ACCs are* Correspondence: cskuo@vghtpe.gov.tw
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reproduction in any medium, provided the oroften hormonally active with glucocorticoid over-secre-
tion, it is a rare cause of Cushing’s syndrome [1]. Here, we
report a case of ACC with initial presentations of hypoka-
lemia and hypertension mimicking hyperaldosteronism.Case presentation
A 65-year-old seemingly well male was referred to our
clinic due to hypertension and hypokalemia. He denied
any discomfort in the past few months. However, vague
symptoms of muscle weakness with cramping, polyuria,
and nocturia were noted upon further interview. During
his annual health check-up six months ago, he was diag-
nosed with hypertension and type 2 diabetes mellitus. On
physical examination, blood pressure was 148/72 mmHg.
There were no purple striae, central obesity, buffalo hump,
proximal muscle weakness, or skin hyperpigmentation.
His serum potassium level was 2.2 mmol/l. Hormonal
studies demonstrated excess of serum cortisol with loss ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Abdomen contrast computed tomography (CT)
showed a 7.8 × 4.8 cm heterogenous lobulated enhancing mass
lesion (arrow) at right adrenal gland with suspicious local
invasion to the posterior segment of liver.
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suppressible dexamethasone test. The aldosterone level
and plasma renin activity were in normal limits. The
laboratory results of hormonal studies are summarized in
Table 1. Abdominal computed tomography (CT) showed
a 7.8 × 4.8 cm heterogenous lobulated enhancing mass
lesion at the right adrenal gland with suspicious local
invasion to the posterior segment of the liver (Figure 1).
To reduce the cortisol level before operation, etomidate
2 mg/hr was infused and the serum cortisol level decrea-
sed from 59.95 μg/dl to 13.3 μg/dl in 48 hours. One week
after diagnosis, he received surgical removal of his right
adrenal tumor, retrocaval lymph nodes and wedge resec-
tion of the liver. Grossly, it was a bulky tumor, measuring
11.6 × 7.0 × 5.1 cm in size with irregular border and cen-
tral necrosis. Microscopic examination revealed a sheet
architectural pattern and focal necrosis. The neoplastic
cells had acidophilic cytoplasm with pleomorphism,
hyperchromasia, and high nuclear grade. There was sinus-
oidal and capsular invasion. The immunohistochemical
stains revealed that the tumor cells were immunoreactive
for melan A and alpha-inhibin diffusely and for calretinin
focally. Based on the Weiss system, the tumor was classi-
fied as adrenocortical carcinoma. The liver and the
retrocaval lymph nodes showed evidence of metastasis
(Figure 2). According to the European Network for the
Study of Adrenal Tumors (ENSAT) staging system, the
tumor was classified as T4N1M1, stage IV. Shortly after
the operation, the patient presented with severe sepsis
with recurrent hypercortisolism. The patient and hisTable 1 Results of hormone studies
Hormone Concentration Reference
Basal hormones
08:00 AM Serum Cortisol (μg/dl) 40.75 5–25
22:00 PM Serum Cortisol (μg/dl) 37.28 <5
08:00 AM ACTH (pg/dl) <5 <46
22:00 PM ACTH (pg/dl) <5 <46
Urinary free cortisol (μg/day) 2584 20–80
Plasma renin activity (pg/ml) 14.81 3–33
Plasma aldosterone (pg/ml) 270 10–310
Urinary VMA (mg/day) 3.9 1.0–7.0
Serum DHEA-S (μmol/l) 2.47 2.49–13.9
High-dose dexamethasone testa
Serum cortisol (μg/dl) 59.85 <46
Urinary free cortisol (μg/day) 4380 20–80
ACTH, adrenocorticotrophic hormone; VMA, vanillylmandelic acid; DHEA-S,
dehydroepiandrosterone sulfate.
aDexamethasone (2 mg) was taken orally every 6 h at 9 AM, 3 PM, 9 PM and
3 AM for a total of eight doses. Blood was drawn 4 h after the last dose and
24 h urine was collected for measurement of the urine free cortisol level from
9 AM on the second day to 9 AM on the third day of
dexamethasone administration.family refused further therapy under critical status and the
patient died as a result of Fournier’s gangrene with septic
shock on the 59th day after diagnosis.
Discussion
The patient was initially referred to our clinic under the
suspicion of hyperaldosteronism due to hypokalemia
and new onset hypertension. Nevertheless, his serum
aldosterone and plasma renin activity were within nor-
mal limits. Instead, Cushing’s syndrome was confirmed
by loss of diurnal cortisol and adrenocorticotrophic
hormone (ACTH) patterns, markedly elevated urine free
cortisol level and a non-suppressible dexamethasone
test. Excessive cortisol overwhelms the capacity of 11β-
hydroxysteroid dehydrogenase type 2 in the proximal
tubule to inactivate cortisol to cortisone, thus allowing
cortisol to saturate the mineralocorticoid receptor, caus-
ing severe hypokalemia in our patient [3].
The image features suggestive of ACC in our case in-
cluded large tumor size (> 4 cm) with irregular margins,
heterogeneous appearance, and local invasion of the liver
[4]. Some authors suggested that magnetic resonance
imaging (MRI) is superior in assessing the extent of liver
metastasis and invasion into adjacent organs and vessels,
especially thrombi in the inferior vena cava [5]. MRI also
offers additional information on chemical shift imaging in
the differentiation of benign or malignant lesions [6,7].
However, MRI as an initial imaging modality is less
standardized probably due to its high expense. Recently,
fluorodeoxyglucose-positron emission tomography (FDG-
PET) has emerged as a useful adjuvant method in differ-
entiating adrenal lesions. High 18 F-FDG uptake implies
increased glucose metabolism and suggests malignancy
Figure 2 The pathological findings of the tumor showed (A) sinusoidal and capsular invasion with irregular border (hematoxylin and
eosin, 40×), (B) sheet-like arrangement (40×), (C) central necrosis (100×), (D) high grade nucleus with frequent mitoses (400×), and
positive immunohistochemical staining for both (E) melan A and (F) alpha-inhibin.
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practice.
Differentiating ACC from benign adenoma microscop-
ically is a challenging issue even for experienced pathol-
ogists. The Weiss System has been the standard method
for decades. Fulfilling more than three of the nine
following histologic features is regarded as malignancy:
(1) high nuclear grade 3 or 4; (2) mitotic rate greater
than 5/50 high-power fields (HPF); (3) atypical mitoses;
(4) tumors with 25% or less clear cells; (5) diffuse archi-
tecture more than 1/3; (6) microscopic necrosis; and (7)
venous, (8) sinusoidal, and (9) capsular invasion [9]. It
was not until recently that a modified Weiss System was
proposed. The modified system aimed to eliminate the
subjective items and suggested a score of ≥3 (2 ×mitotic
rate > 5/50HPF + 2 × clear cells < 25% cytoplasm + abnor-
mal mitoses + necrosis + capsular invasion) as having
malignant behavior [10]. Our patient scored 7 in the
Weiss System and 5 in the modified Weiss System, both
confirming the malignant nature of the disease.
Management for ACC requires a multidisciplinary
approach. The principal considerations are surgical, whichis the only curative option for ACC. For cortisol-secreting
tumors with a urine free cortisol level more than 700–
800 μg/day, short-term use of etomidate for rapid control
of cortisol level before operation was performed in our
Endocrine Unit to minimize surgical risk such as post-
operation infection and poor wound healing. Etomidate as
a steroidogenesis inhibitor, is an imidazole derivative that
was initially used for rapid hypnosis induction [11]. Its use
for rapid sequence intubation in septic patients was asso-
ciated with increased mortality and adrenal insufficiency
according to a recent meta-analysis [12]. Based on small
series, case report studies and consensus guidelines,
hypercortisolism may present as a medical emergency
with severe metabolic disarrangement and the use of
etomidate for rapid control of hypercortisolism is gener-
ally safe if closely monitored and titrated in the hands of
experienced endocrinologists [13]. The recommended
infusion rate for hypercortisolism was 0.04-0.05 mg/kg/hr,
a dose much lower than when used to induce ane-
sthesia. While it rarely causes hepatotoxicity, dose
adjustment in the elderly and patients with renal insuf-
ficiency is needed [13].
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relies on mitotane-based chemotherapy, albeit a low
response rate [14]. Our patient presented with overt
biochemical Cushing’s syndrome without the classical
clinical features, which suggests a rapidly progressing
tumor. Combination therapy with mitotane plus EDP
(etoposide, doxorubicin and cisplatin) may be considered
according to the results of the FIRM-ACT study [15].
The 5-year survival rate of stage IV ACC is less than
25% despite treatment. Poor prognostic factors including
old age, high stage, and cortisol hypersecretion all exis-
ted in our patient, predicting a lesser chance of survival
despite aggressive therapy [16].
Conclusions
We report a case of rapidly progressive stage IV ACC
with liver metastasis and cortisol excess in a seemingly
well individual with hypertension and hypokalemia. Poor
prognosis was anticipated in our patient with old age,
high stage, and cortisol hypersecretion.
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